A study out of Israel shows Pfizer’s COVID-19 vaccine is highly effective in patients with cancer; women with alcohol disorders face adverse health consequences sooner; hundreds of thousands of doses of Johnson & Johnson’s COVID-19 vaccine may expire in June.
Among 102 patients with cancer being monitored at Beilinson Hospital in Petah Tikva, Israel, 9 of 10 developed high antibody levels following their second dose of the Pfizer/BioNTech COVID-19 vaccine, reports JAMA Oncology. The study is ongoing, and the patients with various cancers are being continuously monitored for changes in their antibody levels. Despite overall lower levels of antibodies seen in the study cohort and fewer developing antibodies overall vs healthy controls, the investigators remain hopeful. “The levels are still 20 times above the point that makes you considered positive for antibodies,” stated Salomon M. Stemmer, MD, director of oncology research at Beilinson.
Women are now drinking more, often as much as men—having closed the gender gap in risky drinking habits from a 3:1 ratio to almost 1:1—reports Kaiser Health News. The adverse health consequences of their greater consumption are showing up sooner, too, and include liver and heart disease, as well as cancer. Women are also more likely to suffer brain damage and develop depression faster compared with men. Still, they are less likely to get help, which worries experts who express concern that the COVID-19 pandemic will exacerbate these drinking patterns.
As vaccination rates have dropped significantly in recent weeks, concern has grown among state public health officials that hundreds of thousands of the Johnson & Johnson (J&J) 1-shot COVID-19 vaccine may go to waste, according to The New York Times. In total, more than 10 million J&J doses sit unused in the states that have received them. Andy Slavitt, the White House’s senior advisor for COVID-19 response, is recommending that governors collaborate with the FDA to come up with optimal storage procedures for the doses, which require normal refrigeration but can only be stored in this manner for 3 months—unlike the Pfizer/BioNTech vaccine that has a 6-month shelf life.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More